VIVUS (VVUS) Slashes Workforce as Obesity Market Shrinks
Isis Pharma (ISIS) Nabs $65 Million Upfront in Antisense Deal With AstraZeneca PLC (AZN)
Spree Continues as Shire (SHPG) Snaps Up New York Eye Drop Developer for $300 Million
In A Story of Bribery, Sex Tapes and Political Intrigue, GlaxoSmithKline (GSK) Rehires Former Exec Linked to China Scandal
Lexicon Pharma (LXRX) Surges as Telotristat Meets Goals in Phase III Study
Pfizer (PFE) Grabs Commercialization Rights of Potential MS Generic Treatment Glatiramer Acetate
AstraZeneca PLC (AZN) Halts Three Clinical Trial Programs, Reports Six Quarters of Top-line Growth
Watch Out Gilead (GILD), Investors Feel Vertex (VRTX) May Be Biogen (BIIB)'s Good Fit
Four Boston Biotechs That Could Make M&A Moves This Year
PAREXEL International (PRXL) Stays Mum as 200 Ex-GlaxoSmithKline (GSK) Workers are Reportedly Being Laid Off Today
FDA OKs Juno (JUNO)'s IND for Lead Leukemia Candidate JCAR015
CRO INC Research (INCR) Hires 500 Worldwide with 400 More, Opens Site Advocacy Group
Amneal to Create Up to 300 Jobs at Former Johnson & Johnson (JNJ) Site in Ireland
Abbott (ABT) Snags Tendyne for $225 Million, Cephea Valve for Undisclosed Sum
New Jersey is Competitive in Biotech, But Falls Behind Boston and Bay Area
Pfizer (PFE) CEO on the Prowl for New Acquisitions
Step Aside Juno (JUNO): World's Richest Doctor Pulls Off Largest Biotech IPO Ever
Despite Ramping Up In-House R&D, Eli Lilly (LLY) and Pfizer (PFE) Remain Committed to CROs
See All News >
//-->